Dr. Minal Barve, M.D.
What this data tells you about Dr. Barve
Dr. Minal Barve is a medical oncology specialist in Dallas, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Barve performed 57,484 Medicare services across 2,795 unique beneficiaries.
Between the years covered by Open Payments, Dr. Barve received a total of $23,971 from 35 pharmaceutical and/or device companies across 131 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Barve is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 11,400 | $43 | $136 |
| Anti-nausea injection (fosaprepitant) | 9,300 | $0 | $5 |
| Filgrastim injection (Zarxio) for white blood cells | 7,320 | $0 | $2 |
| Darbepoetin injection (Aranesp) for anemia | 5,855 | $2 | $20 |
| Iron sucrose injection (Venofer) | 5,600 | $0 | $2 |
| Paclitaxel chemotherapy injection | 4,602 | $0 | $8 |
| Immune globulin infusion (Octagam) | 2,300 | $33 | $232 |
| Dexamethasone injection (steroid) | 1,108 | $0 | $1 |
| Denosumab injection (Prolia/Xgeva) | 1,020 | $18 | $65 |
| Blood draw (venipuncture) | 838 | $8 | $20 |
| Comprehensive metabolic blood panel | 761 | $10 | $64 |
| Complete blood count (CBC) with differential | 749 | $8 | $36 |
| Injection, granisetron hydrochloride, 100 mcg | 730 | $0 | $24 |
| Anti-nausea injection (Aloxi/palonosetron) | 720 | $1 | $114 |
| Lactate dehydrogenase (enzyme) level | 624 | $6 | $31 |
| Magnesium level test | 569 | $7 | $29 |
| Office visit, established patient (30-39 min) | 342 | $91 | $368 |
| Immunoglobulin level test | 273 | $9 | $56 |
| Office visit, established patient, complex (40-54 min) | 264 | $136 | $496 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 250 | $23 | $157 |
| Administration of chemotherapy into vein, 1 hour or less | 245 | $102 | $707 |
| Injection, carboplatin, 50 mg | 213 | $2 | $300 |
| Measurement of immunoglobulin light chains | 176 | $17 | $60 |
| Ferritin level test (iron stores) | 173 | $13 | $60 |
| Iron level test | 165 | $6 | $27 |
| Iron binding capacity test | 165 | $9 | $35 |
| Injection, zoledronic acid, 1 mg | 160 | $7 | $431 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 125 | $3 | $373 |
| Drug injection, under skin or into muscle | 113 | $11 | $96 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 100 | $50 | $313 |
| Office visit, established patient (20-29 min) | 92 | $61 | $250 |
| Injection of additional new drug or substance into vein | 86 | $12 | $108 |
| Infusion, normal saline solution , 1000 cc | 84 | $2 | $19 |
| Microscopic examination for white blood cells with manual cell count | 82 | $4 | $22 |
| Complete blood count (CBC), automated | 82 | $6 | $34 |
| Carcinoembryonic antigen (cea) protein level | 75 | $19 | $99 |
| Injection, diphenhydramine hcl, up to 50 mg | 75 | $1 | $7 |
| Administration of additional new drug or substance into vein, 1 hour or less | 66 | $51 | $344 |
| Uric acid level test | 61 | $4 | $25 |
| Administration of chemotherapy into vein, each additional hour | 59 | $23 | $161 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 54 | $58 | $211 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 53 | $16 | $100 |
| Urinalysis with microscopic exam | 42 | $3 | $28 |
| Unclassified drugs | 40 | $1 | $8 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 36 | $1 | $19 |
| Infusion into a vein for hydration, each additional hour | 34 | $10 | $75 |
| Infusion into a vein for hydration, 31-60 minutes | 28 | $25 | $256 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 28 | $26 | $145 |
| PSA test (prostate cancer screening) | 25 | $18 | $94 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 24 | $91 | $657 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 23 | $1,183 | $4,802 |
| Injection of drug or substance into vein | 20 | $30 | $247 |
| Beta-2 microglobulin (protein) level | 15 | $16 | $96 |
| Drawing of blood for a medical problem | 15 | $67 | $264 |
| New patient office visit, complex (60-74 min) | 14 | $159 | $709 |
| New patient office visit (45-59 min) | 11 | $129 | $565 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (77%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Barve is a mixed practice specialist, with above-average Medicare volume (top 18% in TX), with speaking/promotional industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Barve experienced with pembrolizumab injection (keytruda)?
Does Dr. Barve receive payments from pharmaceutical companies?
How do Dr. Barve's costs compare to other medical oncologists in Dallas?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology